ArticlePDF Available
Case Report
Volume 7 • Issue 4 335
Nose Necrosis in Female Shocked Patient: Conservative Treatment with
Heparin
Marco Stabile MD*, Luca Rosato MD and Valeria Navach MD
Aliation:
Plastic Surgery Unit Piacenza Hospital, Italy
*Corresponding Author
Marco Stabile, Head of Plastic Surgery Unit
Piacenza Hospital, Italy.
E-mail: marcostabile@gmail.com
Citation: Marco Stabile, Luca Rosato, Valeria
Navach. Nose Necrosis in Female Shocked Patient:
Conservative Treatment with Heparin. Archives
of Clinical and Medical Case Reports. 7 (2023):
335-337.
Received: January 06, 2023
Accepted: February 07, 2023
Published: August 03, 2023
Introduction
Acute skin failure is an event in which skin and underlying tissue die
due to hypoperfusion concurrent with a critical illness [1]. Usually skin
hypoperfusion is a late symptom in a shock setting and it is present in
patients with an advanced multiorgan failure (MOF) dysfunction. Acute
skin damage is mainly present in feet and hands as consequence of distal
hypoperfusion due to hypotension or microthrombotic events [2]. Face is
less commonly aected. In some cases of purpura fulminas there is anyway
an important face skin involvement. Purpura fulminans is usually associated
with meningococcal sepsis, varicella, and pneumococcal infections and\or
coagulation disorders [3-4]. We present the clinical case of a young woman
occurring at our hospital with nose skin necrosis as rst sing of shock setting.
Case History
A 38 years old woman presented at the Emergency Department in sleepy
state, generalized malaise and fever unresponsive to paracetamol. The patient
had marbling on the extremities and on the face. The anamnestic investigation
did not reveal anything of clinical signicance. After 24 hours, the clinical
picture turned into septic shock with intravascular disseminated coagulation.
Marbling of the extremities persisted and on the nose it progressed in partial
necrosis. Clinical blood and cerebrospinal uid samples tests were negative;
anyway empiric therapy with vancomycin and meropenem was started.
Renal and hepatic function resulted compromised. Blood support circle
(noradrenaline and dopamine therapy) was administered for the rst 3 days.
Breathing support was necessary for 2 days, and then only occasionally
oxygen support was requested. Subcutaneous therapy with enoxaparine was
administered (4000 UI per day) until discharge. Single dose of Antithrombin
III was given on third day. After 72 hours the patient quickly recovered.
The clinical picture and the multiorgan failure state progressively improved
and patient was transferred from intensive care to infective department. The
specialist haematological consultation and all tests carried didn’t revealed
pathologies of haematological branch.
Three days after recovery the plastic surgeon was called for the evaluation
of facial injuries. The patients showed a full thickness necrosis of the skin of
the tip of nose and faded marbling of the rest of the nose and cheeks (Figure 1).
Conservative treatment was chosen and started with daily topic applications
of "Epsodilave 250 UI / 5ml" (sodic heparin) and greasy gauze dressing. Two
days after, the necrosis showed an improvement and it was limited to the more
distal areas of the nose (Figure 2). The topical treatment continued for 18 days
until the patient was discharged. No surgical or chemical debridement was
carried out. Extremities marbling had a spontaneous regression. One month
later, the patient came to control showing a complete remission and resolution
without signicant scarring (Figure 3).
Marco Stabile MD, et al., Arch Clin Med Case Rep 2023
DOI:10.26502/acmcr.96550625
Citation: Marco Stabile, Luca Rosato, Valeria Navach. Nose Necrosis in Female Shocked Patient: Conservative Treatment with Heparin. Archives
of Clinical and Medical Case Reports. 7 (2023): 335-337.
Volume 7 • Issue 4 336
Discussion
Acute skin necrosis due to severe and prolonged
hypotension can be present in advanced shock settings.
Usually extremities are aected, because of their distinctive
vascular pattern. These signs become evident later respect to
other shock typical symptoms [5]. In our case, skin failure
was an early expression of critical illness status. Later the
patient got worse in a MOF status, with compromised renal
and hepatic function. The unique localization of the nose skin
necrosis addressed clinicians towards a purpura diagnosis.
All examination (blood coagulation pattern, absence of
meningococcal infection in blood and cerebrospinal uid)
contradicted this hypothesis. The hematologist also excluded
any disease of hiss clinical branch. We nally concluded the
damage at nose skin was due solely to hypoperfusion. Nose
has a rich vascularization from facial artery in the lower part
and from angular branch in the upper part. All these branches
anastomose at the lateral sides. Nasal tip lacks anyway of a
strong vascularization and it is more prone to hypoperfusion.
There are not standardized treatments for acute skin
failure, maybe also because in a life threatening setting,
treatment of skin lesions is not considered relevant. Minor
lesions can regress after reset of blood circle, but established
skin necrosis needs specic treatment. The nasal soft tissue
envelope is composed of fat, muscle, overlying supercial
musculoaponeurotic system, and skin. The caudal half of
the nose contains also a higher density of sebaceous glands
[6]. Surgical debridement in case of nose skin necrosis
is commonly discouraged. The deeper sebaceous layers
especially at the tip, have an important regenerative capacity,
so conservative procedures are preferred. Many topical
treatments are described in literature. Use of vasodilators
such as ointment with nitroglycerine and systemic or topical
treatment with pentoxifylline or prostaglandin E1 were used.
Hyperbaric treatment is also described by some authors. The
cost and the management of these treatments are not often
suitable for critical illness patients. In our experience, we had
good results in the topic use of heparin on burns and skin
necrosis, that’s why we routinely use it for cutaneous lesions
that need conservative treatment.
Ng in his review of literature underlines that topic
treatment with gel containing heparin improves or positively
alter the microcirculation in normal skin at both deep
and supercial capillary layers [7]. Also patients with
microangiopathy and have a signicant improvement after
treatment with topical use of heparin. Heparin molecule is
a long glycosamminoglicane. Apart its role in coagulation
process, it has also anti-inammatory property. For this
reason heparin and its derivate are also used in the treatment
of asthma, inammatory bowel disease, cardiopulmonary
bypass, and cataract surgery [8]. Many mechanisms
are involved in the anti-inammatory eect. Levels of
Figure 1: Full thickness necrosis of the skin of the tip of nose and
faded marbling of the rest of the nose and cheeks.
Figure 2: The necrosis showed an improvement and limited to the
more distal areas of the nose.
Figure 3: Complete remission and resolution without signicant
scarring.
Marco Stabile MD, et al., Arch Clin Med Case Rep 2023
DOI:10.26502/acmcr.96550625
Citation: Marco Stabile, Luca Rosato, Valeria Navach. Nose Necrosis in Female Shocked Patient: Conservative Treatment with Heparin. Archives
of Clinical and Medical Case Reports. 7 (2023): 335-337.
Volume 7 • Issue 4 337
citocytokines after heparin administration are decreased (IL
6, IL 8, TNF) and heparin also inhibits adhesion of leukocytes
and neutrophils to endothelial cells.
The topical use of heparin on damaged skin has been long
described in the treatment of burns by Saliba with excellent
results in terms of healing; scarring and pain control [9-10].
At our advice the use of topical heparin is a valid treatment
in case of skin damage due to vascular impairment. We
recommend trying this before surgical debridement.
References
1. Langemo DK, Brown G. Skin fails too: acute, chronic,
and end-stage skin failure. Adv Skin Wound Care 19
(2006): 206-211.
2. Dalgleish L, Campbell J, Finlayson K, et al. Acute Skin
Failure in the Critically Ill Adult Population: A Systematic
Review. Adv Skin Wound Care 33 (2020): 76-83.
3. Moon SM, Hong YS, Lee DS, et al. Purpura fulminans
on the nose with septic abortion. Intensive Care Med 41
(2015): 1122.
4. Walsh LF, Sherbuk JE, Wispelwey B. Pneumococcal
induced thrombotic thrombocytopenic purpura with
features of purpura fulminans. BMJ Case Rep 14 (2021):
e235580.
5. Warkentin TE, Ning S. Symmetrical peripheral gangrene
in critical illness. Transfus Apher Sci 60 (2021): 103094.
6. Kerolus JL, Nassif PS. Treatment Protocol for
Compromised Nasal Skin. Facial Plast Surg Clin North
Am 27 (2019): 505-511.
7. Ng L, Monagle K, Monagle P, et al. Topical use of
antithrombotics: review of literature..Thromb Res 135
(2015): 575-581.
8. Mousavi S, Moradi M, Khorshidahmad T, et al. Anti-
Inammatory Eects of Heparin and Its Derivatives: A
Systematic Review. Adv Pharmacol Sci 2015 (2015):
507151.
9. Heparin in the treatment of burns: a review. Saliba MJ
Jr.Burns 27 (2001): 349-358.
10. Venakatachalapathy TS, Mohan Kumar S, Saliba MJ. A
comparative study of burns treated with topical heparin
and without heparin. Ann Burns Fire Disasters 20
(2007):189-198.
... 7-10 More importantly, from a clinical perspective, there is abundant clinical evidence of the benefits of topical heparin and heparin derivatives in treating severely inflammatory skin conditions, such as burns [21][22][23] and skin necrosis associated with septic shock hypoperfusion because of intravascular disseminated coagulation, even as alternatives to surgical debridement. 24 Speculatively, all conditions secondary to intra-arterial occlusion should benefit from the peculiar topical heparin pharmacodynamics and ease of application as salvage add-on co-treatment, ranging from early pain, skin hyperemia, and livedo reticularis to late necrosis. 10 Although the rationale for combining hyaluronidase and topical heparin may be sound, the preliminary report of 2 episodic pieces of evidence needs a more rigorous demonstration. ...
Article
Full-text available
Hyaluronic acid fillers rarely cause potentially devastating occlusive adverse events that require immediate hyaluronidase salvage infiltrations. An exploratory photographic investigation probed whether topical heparin's anticlotting and anti-inflammatory properties could synergize with and enhance the effectiveness of hyaluronidase. Based on heparin pharmacodynamics, the authors explored the rationale for associating topical heparins with hyaluronidase in treating occlusive side effects following accidental intra-arterial hyaluronic acid injections. In the first case, an occlusion in the right superior labial artery area, highlighted by reddish-blue net-like skin discoloration (livedo reticularis), developed below the nasal pyramid shortly after 3 intradermal injections of low-viscosity hyaluronic acid gel, rapidly progressing to the glabellar and forehead regions. Within 1 h after the hyaluronidase salvage injection (80 IU), topical low-molecular-weight heparin (40 mg enoxaparin) was uniformly applied, and the procedure was repeated every 8 h for 15 days. In the second case, a cluster of severe occlusive lesions developed in the nose and nasal tip areas after 3 hyaluronic acid injections (formulation and doses as previously stated). After the first week, enoxaparin (4000 IU) was applied topically every 8 h for an additional 3 weeks. Two sequences of photographs document the occlusions’ evolution toward almost complete skin repair after 28 days (first case: immediate combined treatment) and 15 days (second case: sequential treatment spaced 1 week). The anti-inflammatory and antithrombotic pharmacodynamics of heparin and heparin derivatives offer a promising rationale as an add-on option (combined hyaluronidase and topical heparin) to treat the occlusive side effects caused by hyaluronic acid. Level of Evidence: 5 (Therapeutic)
... The versatility of this technique is easy to perform when you are alone confined at home such as in these cases during the pandemic. The open dressing allows direct visualization of the burn area and the vision of healing progression [6] and allow to touch the burned area as little as possible while the re-epithelialization process takes place. The simple topic application in the open air avoid to purchase gauze and reduces costs. ...
Article
Full-text available
The utilization of telemedicine has gained prominence, especially in times of restricted physical interaction due to the COVID-19 pandemic. We present a successful healing for domestic second-degree burn injuries solely through telemedicine-guided treatment, employing topical heparin as a pivotal therapeutic agent. This work examines the efficacy and challenges of this remote healing approach, shedding light on the potential of simple treatment with topical heparin in optimizing wound management in superficial burn patients, even from a distance.
... The versatility of this technique is easy to perform when you are alone confined at home such as in these cases during the pandemic. The open dressing allows direct visualization of the burn area and the vision of healing progression [6] and allow to touch the burned area as little as possible while the re-epithelialization process takes place. The simple topic application in the open air avoid to purchase gauze and reduces costs. ...
Article
Full-text available
Easy method with TOPICAL HEPARIN to treat the second degree of burn skin in open air, avoiding painful daily medications
Article
Full-text available
Symmetrical peripheral gangrene (SPG) is a disabling complication that affects a small proportion of patients who survive critical illness. Its pathogenesis reflects profoundly disturbed procoagulant-anticoagulant balance in susceptible tissue beds secondary to circulatory shock (cardiogenic, septic). There is a characteristic SPG triad: (a) shock (hypotension, lactic acidemia, normoblastemia, multiple organ dysfunction), (b) disseminated intravascular coagulation (DIC), and (c) natural anticoagulant depletion (protein C, antithrombin). In recent years, risk factors for natural anticoagulation depletion have been identified, most notably acute ischemic hepatitis (“shock liver”), which is seen in at least 90% of patients who develop SPG. Moreover, there is a characteristic time interval (2 to 5 days, median 3 days) between the onset of shock/shock liver and the beginning of ischemic injury secondary to peripheral microthrombosis (“limb ischemia with pulses”), reflecting the time required to develop severe depletion in hepatically-synthesized natural anticoagulants. Other risk factors for natural anticoagulant depletion include chronic liver disease (e.g., cirrhosis) and, possibly, transfusion of colloids (albumin, high-dose immunoglobulin) lacking coagulation factors. A causal role for vasopressor therapy is unproven and is unlikely; this is because critically ill patients who develop SPG do so usually after at least 36 to 48 hours of vasopressor therapy, implicating a time-dependent pathophysiological mechanism. The most plausible explanation is a progressive time-dependent decline in key natural anticoagulant factors, reflecting ongoing DIC (“consumption”), proximate liver disease whether acute or chronic (“impaired production”), and colloid administration (“hemodilution”). Given these evolving concepts of pathogenesis, a rationale approach to prevention/treatment of SPG can be developed.
Article
Full-text available
Background. Heparin, used clinically as an anticoagulant, also has anti-inflammatory properties. The purpose of this systematic review was to provide a comprehensive review regarding the efficacy and safety of heparin and its derivatives as anti-inflammatory agents. Methods. We searched the following databases up to March 2012: Pub Med, Scopus, Web of Science, Ovid, Elsevier, and Google Scholar using combination of Mesh terms. Randomized Clinical Trials (RCTs) and trials with quasi-experimental design in clinical setting published in English were included. Quality assessments of RCTs were performed using Jadad score and Consolidated Standards of Reporting Trials (CONSORT) checklist. Results. A total of 280 relevant studies were reviewed and 57 studies met the inclusion criteria. Among them 48 studies were RCTs. About 65% of articles had score of 3 and higher according to Jadad score. Twelve studies had a quality score > 40% according to CONSORT items. Asthma (n = 7), inflammatory bowel disease (n = 5), cardiopulmonary bypass (n = 8), and cataract surgery (n = 6) were the most studied disease condition. Forty studies use unfractionated heparin (UFH) for intervention; the remaining studies use low molecular weight heparin (LMWH). Conclusion. Despite the conflicting results, heparin seems to be a safe and effective anti-inflammatory agent; although it is shown that heparin can decrease the level of inflammatory biomarkers and improves patient conditions, still more data from larger rigorously designed studies are needed to support use of heparin as an anti-inflammatory agent in clinical setting. However, because of the association between inflammation, atherogenesis, thrombogenesis, and cell proliferation, heparin and related compounds with pleiotropic effects may have greater therapeutic efficacy than compounds acting against a single target.
Article
Full-text available
Following reports of heparin use in burn treatment, an ethics-committee-approved prospective randomized study with controls compared results obtained using traditional usual burn treatment without heparin with results in similar patients similarly treated with heparin added topically. The subjects were 100 consecutive burn patients (age, 15-35 yr) with second-degree superficial and deep burns of 5-45% TBSA size. Two largely similar cohort groups, i.e. a control group (C) and a heparin group (H) with 50 subjects per group, were randomly treated, the main difference between the groups being that 13 C patients had burns of 35-45% extent vs. only one such patient in H (p < 0.01). The 50 C patients received traditional routine treatment, including topical antimicrobial cream, debridement, and, when needed, skin grafts in the early post-burn period. The 50 H patients, without topical cream, were additionally treated, starting on day 1 post-burn, with 200 IU/ml sodium aqueous heparin solution USP (heparin) dripped on the burn surfaces and inserted into the blisters 2-4 times a day for 1-2 days, and then only on burn surfaces for a total of 5-7 days, prior to skin grafting, when needed. Thereafter, C and H treatment was similar. It was found that the H patients complained of less pain and received less pain medicine than the C patients. H needed fewer dressings and oral antibiotics than C. Significantly less intravenous fluid was infused in H: 33.5 litres in 39 H patients vs. 65 litres in 41 C patients, i.e. nearly 50% less (p < 0.04). The 50 H patients had four skin graftings (8%), while the 50 C patients had 10 (20%). Five 5 C patients died (mortality, 10%). No H patients died. The number of days in hospital for H vs. C was significantly less (overall, p < 0.0001): 58% of H were discharged within 10 days vs. 6% of C; 82% of H were out in 20 days vs. 14% of C; 98% of H vs. 44% of C were out in 30 days; and while 100% of H were discharged by day 40, 56% of C required up to another 10 days. The burns in H patients healed on average in 15 days (maximum period 37 days) vs. an average of 25 days (maximum > 48 days) in C (p < 0.0006). Procedures and costs in H were much reduced compared with C. Photographs of the differences between H and C are presented for the sake of comparison. It is concluded that heparin applied topically for 5-7 days improved burn treatment: it reduced pain, pain medicine, dressings, and use of antibiotics; it significantly reduced IV fluids (p < 0.04), days in hospital (p < 0.0001), and healing time (p < 0.0006); and it reduced skin grafts, mortality, and costs.
Article
Full-text available
To identify what has been published in the literature about acute and chronic skin failure and to propose a working definition of this phenomenon. A systematic review of MEDLINE and CINAHL to determine what has been published in the literature on the topics of skin failure, acute skin failure, chronic skin failure, multiple organ failure, end-of-life skin deterioration, and pressure ulcers in hospice from 1984 to 2005. Published papers were reviewed for content related to acute, chronic, and end-stage skin failure. Seven articles were identified that referenced either acute, chronic, or end-stage skin failure. Additional information was identified that discussed the processes of acute and chronic skin failure and pressure ulcers in individuals in hospice care or at the end of life. Care considerations and dilemmas related to a curative versus palliative goal in wound healing were discussed. Minimal literature exists on skin failure, yet caregivers and the public must be aware of, assess for, and consider this phenomenon in their care. Based on this literature review, skin failure was defined by the authors as an event in which the skin and underlying tissue die due to hypoperfusion that occurs concurrent with severe dysfunction or failure of other organ systems. Skin failure can be categorized as acute, chronic, or end stage. Pressure ulcers, a type of skin death, frequently occur in persons with a heavy disease burden, especially those at or near the end of life, despite good care.
Article
A 42-year-old woman with a history of acute myeloid leukaemia status postallogeneic stem cell transplant presented with fevers, altered mental status, pulmonary infiltrates and septic shock that further progressed to thrombocytopenia and purpura fulminans. Laboratory studies were consistent with a diagnosis of thrombotic thrombocytopenic purpura (TTP). Blood cultures grew Streptococcus pneumoniae . On chart review, our patient had a history of low immunoglobulin levels following stem cell transplant, which may have predisposed her to pneumococcal infection. The patient responded to therapy with ceftriaxone, plasma exchange, rituximab and caplacizumab. This is the fourth-documented case of pneumococcal induced TTP and, to the best of our knowledge, the first-describing pneumococcal induced TTP with purpura fulminans. We conclude that patients with TTP should be evaluated for infectious aetiologies and empiric antibiotics should be considered. Clinicians should be aware of the possibility for TTP to lead to purpura fulminans.
Article
General purpose: To present a systematic review of the literature conducted to define and extend knowledge of the risk factors, causes, and antecedent conditions of acute skin failure (ASF) in adult intensive care patients. Target audience: This continuing education activity is intended for physicians, physician assistants, nurse practitioners, and nurses with an interest in skin and wound care. Learning objectives/outcomes: After participating in this educational activity, the participant should be better able to:1. Outline the background information helpful for understanding the authors' systematic review of ASF in adult intensive care patients.2. Summarize the results of the authors' review of the risk factors, causes, and antecedent conditions of ASF in adult intensive care patients. Abstract: To define and extend knowledge of the risk factors, causes, and antecedent conditions of acute skin failure (ASF) in the adult intensive care patient cohort.The Cochrane Library, Joanna Briggs Institute Evidence-Based Practice Database, PubMed, Medical Literature Analysis and Retrieval System, Cumulative Index of Nursing and Allied Health Literature, and Google Scholar.Studies were selected if they were qualitative or quantitative research that reported ASF in adult human patients in an ICU setting. The preliminary search yielded 991 records and 22 full texts were assessed for eligibility. A total of three records were included. Studies were appraised using the Mixed Methods Appraisal Tool.Data from the included studies were extracted by one reviewer and summarized in data collection tables that were checked and verified by a second reviewer.Study authors identified five independent predictors of ASF: peripheral vascular disease, mechanical ventilation longer than 72 hours, respiratory failure, liver failure, and sepsis. However, the term ASF was applied to retrospective cohorts of patients who developed severe pressure injuries. This, combined with the absence of evidence surrounding the assessment, clinical criteria, and diagnosis of ASF, could impact these variables' predictability relative to the condition.These results highlight a substantial evidence gap regarding the etiology, diagnostic biomarkers, and predictors of ASF. Further research focused on these gaps may contribute to an accurate and agreed-upon definition for ASF, as well as improved skin integrity outcomes.
Article
As the number of patients seeking surgical and nonsurgical rhinoplasty continues to increase, the risk of nasal skin compromise after surgery also has risen. Vascular insult to the nasal skin envelope can lead to permanent disfigurement that is nearly impossible to correct. Tissue loss often requires major reconstruction that yields suboptimal cosmetic results. This article discusses prevention, early recognition, and effective treatment that aim to mitigate skin necrosis and the resulting soft tissue destruction.
Article
While antithrombotics are usually administered intravenously, subcutaneously or orally, there are a number of publications reporting topical application of anticoagulation therapy. This paper aims to review the available literature regarding clinical conditions, the details of the topical antithrombotic treatment, as well as positive or adverse effects in an attempt to ascertain the safety and efficacy of this form of treatment. Published literature was searched to identify publications reporting the use of antithrombotic treatments administered via topical application between 1st January1990 and 1st January 2013. There were 43 studies reported in 10 different clinical conditions. Majority of the studies were randomized controlled trials (51.2%), prospective studies (18.6%) or case reports (11.6%). The clinical conditions in which topical antithrombotics were administered included: microangiopathy, acute haemorrhoids, periodontitis, dermatitis, burns, ocular conditions and surgery, blunt force impact, scars, as well as clinical conditions associated with superficial venous thrombosis (SVT). The most commonly used topical antithrombotic was heparin (79.1% of studies). The respective dosage of different antithrombotics varied depending on specific clinical conditions. While most studies reported mean improvements or resolution of symptoms/condition in patients, the patient outcomes were variable. This review demonstrates that topical antithrombotic treatment is used according to a wide variety of protocols, with a subsequent variability in patient outcomes. Specific guidelines for the use of topical antithrombotics should be developed to standardize this form of treatment and ensure the best possible outcomes for patients. Copyright © 2015 Elsevier Ltd. All rights reserved.
Heparin in the treatment of burns: a review
Heparin in the treatment of burns: a review. Saliba MJ Jr.Burns 27 (2001): 349-358.